

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

ډر.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: of Patents and Trademarks, Commissioner Alexandria VA 22313 on

December 11, AND HUESCHEN

SERVIER 339

Applicant

Daniel LESIEUR, Frederique KLUPSCH, Gerald GUILLAUMET,

Marie-Claude VIAUD, Michel LANGLOIS, Caroline

BENNEJEAN, Pierre RENARD, Phillipe DELAGRANGE

Serial No.

09/700,098

Filed

November 10, 2000

Title

New Substituted Cyclic Compounds

Art Unit

1624

Examiner

Kahsay HABTE, Esq.

Honorable Commissioner of Patents and Trademarks Alexandria, VA 22313

RESPONSE AND ELECTION UNDER 37 CFR §§ 1.111 AND 1.142

Sir:

Responsive to the Office Action, a Restriction Requirement, dated November 20, 2003, it is the position of the Office that the application pertains to inventions which are not so linked as to form a general inventive concept. The applicants traverse this conclusion on the grounds that a chemist would not find the instant invention to involve structurally distinct inventions. Absent contradictory evidence that those skilled in the art would find the instant invention to consist of multiple inventions, it is submitted that the Office Requirement is not substantiated.

None-the-less, in an effort to advance the prosecution of the instant application, the applicants elect *with traverse* to prosecute the invention of Claims 1, 3, 5-13, 17-19, 23-25, 30-33, 34, 39, 46, 53-70, 71, 72, 78, and 82-83, directed to Group V of the Restriction Requirement; it being understood that Claims 1, 3, 5-13, 17-19, 23-25, 30-33, 71, 78, and 82-83 will be examined to the extent that they fall within the elected invention. Applicants submit that the compounds of Claim 81 in which A_A is a ring system of formula (b) fall within Group V, therefore, the applicants elect to prosecute these compounds as well. The dependency of Claim 81 will be amended to Claim 1 rather than Claim 74. Applicants designate the Species of Example 1, N-{2-[7-(methylthio)-1-naphthyl]ethyl}acetamide, as representative of Group V.

The Examiner may withdraw all non-elected claims of Groups I-IV and Group VI, without prejudice to their rejoinder during later examination and/or prosecution in a Divisional Application.

Swift and favorable consideration of the instant application is respectfully solicited.

Respectfully submitted,

THE FIRM OF HUESCHEN AND SAGE

BY: FATRICK SAGE

Dated: December 11, 2003 Customer No.: 25,666 5Q0 Columbia Plaza 350 East Michigan Ave. Kalamazoo, MI 49007-3856 (269) 382-0030

Enclosure: Postal Card Receipt

THE COMMISSIONER IS HEREBY AUTHORIZED TO CHARGE ANY FURTHER OR ADDITIONAL FEES WHICH MAY BE REQUIRED (DUE TO OMISSION, DEFICIENCY, OR OTHERWISE), OR TO CREDIT ANY OVERPAYMENT, TO DEPOSIT ACCOUNT NO. 08,3220.